What is the virus that is viral fever of humans and primates and that Triazavirin could have a potential application?
Triazavirin Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has an azoloazine base structure, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including tick-borne encephalitis, and is also being investigated for potential application against Lassa fever and Ebola virus disease.
Reoviridae Reoviridae is a family of viruses. They have a wide host range, including vertebrates, invertebrates, plants, and fungi. They are unique in that they lack lipid envelopes and package their genomes of discrete double-stranded segments of RNA within multi-layered capsids. Lack of a lipid envelope has allowed three-dimensional structures of these large complex viruses (diameter,∼600–1,000 nm) to be obtained. There are currently 87 species in this family, divided among 30 genera. Reoviruses can affect the gastrointestinal system (such as "Rotavirus") and respiratory tract. The name "Reo-" is derived from "respiratory enteric orphan viruses." The term "orphan virus" refers to the fact that some of these viruses have been observed not associated with any known disease. Even though viruses in the Reoviridae family have more recently been identified with various diseases, the original name is still used.